Azitra Inc.
June 16, 2025
Company Presentation
Dermatology
Azitra is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead candidate, ATR-12, is an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. ATR-12 is being evaluated in a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's next most advanced product, is being developed for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has an open IND for a Phase 1/2 clinical trial with ATR-04 in patients with EGFRi associated rash. ATR-12 and ATR-04 were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library. The platform is augmented by AI and ML technology that analyzes, predicts, and helps screen the library of strains for drug like molecules.
Company HQ City:
Branford
Company HQ State:
CT
Company HQ Country:
United States
Year Founded:
2014
Lead Product in Development:
ATR-12
CEO
Francisco Salva
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
Exchange
NSYE: American
Ticker
AZTR
When you expect your next catalyst update?
ATR-12 safety data
What is your next catalyst (value inflection) update?
June 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}